Tonix Pharmaceuticals - TNXP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.20
  • Forecasted Upside: 3,494.16 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.53
+0 (0.00%)

This chart shows the closing price for TNXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tonix Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNXP

Analyst Price Target is $19.20
▲ +3,494.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Tonix Pharmaceuticals in the last 3 months. The average price target is $19.20, with a high forecast of $19.20 and a low forecast of $19.20. The average price target represents a 3,494.16% upside from the last price of $0.53.

This chart shows the closing price for TNXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Tonix Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2022Noble FinancialInitiated CoverageOutperform$19.20High
8/11/2021Alliance Global PartnersLower TargetBuy$128.00 ➝ $64.00High
2/25/2021Alliance Global PartnersBoost TargetBuy$96.00 ➝ $128.00High
8/20/2020Alliance Global PartnersBoost Target$80.00 ➝ $96.00High
8/30/2019Roth CapitalLower TargetBuy$128.00 ➝ $41.60Low
4/18/2019Roth CapitalUpgradeNeutral ➝ Buy$128.00Low
7/27/2018Brookline Capital ManagementDowngradeBuy ➝ HoldLow
7/27/2018B. RileyReiterated RatingBuy ➝ Neutral$2,560.00 ➝ $2,560.00High
7/27/2018Roth CapitalReiterated RatingBuy ➝ Neutral$1,920.00 ➝ $320.00High
6/6/2018B. RileyInitiated CoverageBuy$2,560.00High
5/1/2018Brookline Capital ManagementReiterated RatingBuyLow
12/1/2017AegisReiterated RatingBuyMedium
(Data available from 10/1/2017 forward)

News Sentiment Rating

-1.15 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/5/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/4/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/4/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/3/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/1/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Tonix Pharmaceuticals logo
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Read More

Today's Range

Now: $0.53
Low: $0.52
High: $0.56

50 Day Range

MA: $1.16
Low: $0.53
High: $1.90

52 Week Range

Now: $0.53
Low: $0.52
High: $20.00

Volume

1,378,410 shs

Average Volume

2,733,982 shs

Market Capitalization

$23.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Tonix Pharmaceuticals?

The following sell-side analysts have issued reports on Tonix Pharmaceuticals in the last twelve months: Noble Financial, and StockNews.com.
View the latest analyst ratings for TNXP.

What is the current price target for Tonix Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Tonix Pharmaceuticals in the last year. Their average twelve-month price target is $19.20, suggesting a possible upside of 3,494.2%. Noble Financial has the highest price target set, predicting TNXP will reach $19.20 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $19.20 for Tonix Pharmaceuticals in the next year.
View the latest price targets for TNXP.

What is the current consensus analyst rating for Tonix Pharmaceuticals?

Tonix Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNXP will outperform the market and that investors should add to their positions of Tonix Pharmaceuticals.
View the latest ratings for TNXP.

What other companies compete with Tonix Pharmaceuticals?

How do I contact Tonix Pharmaceuticals' investor relations team?

Tonix Pharmaceuticals' physical mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company's listed phone number is (212) 980-9155 and its investor relations email address is [email protected] The official website for Tonix Pharmaceuticals is www.tonixpharma.com. Learn More about contacing Tonix Pharmaceuticals investor relations.